studies

classical Hodgkin lymphoma (cHL), pembrolizumab based treatment vs. immune chekpoint inhibitors, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsKEYNOTE-204, 2021 0.65 [0.48; 0.88] 0.65[0.48; 0.88]KEYNOTE-204, 202110%304NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-204, 2021 1.68 [1.05; 2.68] 1.68[1.05; 2.68]KEYNOTE-204, 202110%300NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-204, 2021 1.55 [0.26; 9.42] 1.55[0.26; 9.42]KEYNOTE-204, 202110%300NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-204, 2021 0.87 [0.51; 1.47] 0.87[0.51; 1.47]KEYNOTE-204, 202110%300NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.70 [0.40; 1.21] 0.70[0.40; 1.21]KEYNOTE-204, 202110%300NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-204, 2021 2.06 [0.07; 61.91] 2.06[0.07; 61.91]KEYNOTE-204, 202110%300NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-204, 2021 0.75 [0.39; 1.43] 0.75[0.39; 1.43]KEYNOTE-204, 202110%300NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 2.06 [0.07; 61.91] 2.06[0.07; 61.91]KEYNOTE-204, 202110%300NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 4.15 [0.19; 92.82] 4.15[0.19; 92.82]KEYNOTE-204, 202110%300NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.06; 16.58] 1.03[0.06; 16.58]KEYNOTE-204, 202110%300NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.51 [0.02; 15.37] 0.51[0.02; 15.37]KEYNOTE-204, 202110%300NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.02; 52.11] 1.03[0.02; 52.11]KEYNOTE-204, 202110%300NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 4.15 [0.19; 92.82] 4.15[0.19; 92.82]KEYNOTE-204, 202110%300NAnot evaluable Eczema TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.51 [0.02; 15.37] 0.51[0.02; 15.37]KEYNOTE-204, 202110%300NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.02; 52.11] 1.03[0.02; 52.11]KEYNOTE-204, 202110%300NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.51 [0.02; 15.37] 0.51[0.02; 15.37]KEYNOTE-204, 202110%300NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.02; 52.11] 1.03[0.02; 52.11]KEYNOTE-204, 202110%300NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.02; 52.11] 1.03[0.02; 52.11]KEYNOTE-204, 202110%300NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.51 [0.02; 15.37] 0.51[0.02; 15.37]KEYNOTE-204, 202110%300NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.51 [0.02; 15.37] 0.51[0.02; 15.37]KEYNOTE-204, 202110%300NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.17 [0.01; 3.39] 0.17[0.01; 3.39]KEYNOTE-204, 202110%300NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.17 [0.01; 3.39] 0.17[0.01; 3.39]KEYNOTE-204, 202110%300NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 2.06 [0.07; 61.91] 2.06[0.07; 61.91]KEYNOTE-204, 202110%300NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.02; 52.11] 1.03[0.02; 52.11]KEYNOTE-204, 202110%300NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 2.06 [0.07; 61.91] 2.06[0.07; 61.91]KEYNOTE-204, 202110%300NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.27 [0.07; 0.97] 0.27[0.07; 0.97]KEYNOTE-204, 202110%300NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 0.25 [0.01; 5.69] 0.25[0.01; 5.69]KEYNOTE-204, 202110%300NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.14; 7.39] 1.03[0.14; 7.39]KEYNOTE-204, 202110%300NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 6.38 [0.76; 53.66] 6.38[0.76; 53.66]KEYNOTE-204, 202110%300NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.02; 52.11] 1.03[0.02; 52.11]KEYNOTE-204, 202110%300NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 2.06 [0.07; 61.91] 2.06[0.07; 61.91]KEYNOTE-204, 202110%300NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 1.03 [0.02; 52.11] 1.03[0.02; 52.11]KEYNOTE-204, 202110%300NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 4.15 [0.19; 92.82] 4.15[0.19; 92.82]KEYNOTE-204, 202110%300NAnot evaluable Urticaria TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 2.06 [0.07; 61.91] 2.06[0.07; 61.91]KEYNOTE-204, 202110%300NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-204, 2021 2.06 [0.07; 61.91] 2.06[0.07; 61.91]KEYNOTE-204, 202110%300NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-11-05 18:25 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 73,232,233 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561